EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?

This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY).

The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting stent).

Landmark analyses at one year had revealed an advantage in favor of new devices as regards the rates of revascularization and other secondary endpoints. However, at the two-year follow-up, these differences were leveled out.

Original title: Two-Year Clinical Outcome of All-Comers Treated with Three Highly Dissimilar Contemporary Coronary Drug-Eluting Stents in the Randomized BIO-RESORT Trial.

Presenter: Marlies M. Kok.

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.